公开(公告)号：US20120190726A1

公开(公告)日：2012-07-26

申请号：US13335724

申请日：2011-12-22

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A61K31/7088 ,  C08B37/18 ,  A61K31/713

CPC classification number: A61K31/7088 ,  A61K31/713 ,  A61K48/00 ,  C08B37/0009 ,  C08L5/00 ,  C12N15/87

Abstract: Embodiments of the invention include functionalized polysaccharides and compositions and structures including the same. In an embodiment, the invention includes an active agent delivery composition including a polysaccharide functionalized with a coupling group, wherein the polysaccharide lacks charged groups at a pH of between 6 and 8; and a complex comprising a nucleic acid and a transfection agent. In an embodiment, the invention includes an active agent delivery structure including a matrix comprising a polysaccharide covalently cross-linked through the residue of a coupling group on the polysaccharide, the polysaccharide lacking charged groups at a pH of between 6 and 8; and a nucleic acid delivery complex disposed within the active agent delivery structure. In an embodiment, the invention includes a material for medical applications including glycogen functionalized with coupling groups at a degree of substitution of between about 0.01 and 0.5. Other embodiments are also included herein.

Abstract translation: 本发明的实施方案包括官能化多糖及包含其的组合物和结构。 在一个实施方案中，本发明包括活性剂递送组合物，其包含用偶联基团官能化的多糖，其中所述多糖在6至8的pH下缺少带电基团; 和包含核酸和转染剂的复合物。 在一个实施方案中，本发明包括活性剂递送结构，所述活性剂递送结构包括通过多糖上的偶联基团的残基共价交联的多糖的基质，pH在6至8之间缺少带电基团的多糖; 以及设置在活性剂递送结构内的核酸递送复合物。 在一个实施方案中，本发明包括用于医疗应用的材料，包括以约0.01至0.5的取代度的偶联基团官能化的糖原。 本文还包括其它实施例。

公开(公告)号：US20100166829A1

公开(公告)日：2010-07-01

申请号：US12647780

申请日：2009-12-28

Applicant: Joram Slager ,  Aron B. Anderson

Inventor： Joram Slager ,  Aron B. Anderson

IPC: A61F2/00 ,  A61K9/00 ,  A61K39/395

CPC classification number: A61L27/48 ,  A61L27/54 ,  A61L31/129 ,  A61L31/16 ,  A61L2300/252 ,  A61L2300/256 ,  A61L2300/622 ,  C08L71/02 ,  C08L31/04 ,  C08L33/10

Abstract: The present invention is directed to polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the elution control matrix includes a polymeric matrix having a first polymer and a plurality of microparticles that include the hydrophilic bioactive agent. In one embodiment, the matrix includes a polymer comprising hydrophilic and hydrophobic portions. In another embodiment, the microparticles include a crosslinked hydrophilic polymer.

Abstract translation: 本发明涉及用于控制释放亲水生物活性剂的聚合物基质。 通常，洗脱控制基质包括具有第一聚合物和包含亲水生物活性剂的多个微粒的聚合物基质。 在一个实施方案中，基质包括包含亲水和疏水部分的聚合物。 在另一个实施方案中，微粒包括交联的亲水性聚合物。

公开(公告)号：US07638344B2

公开(公告)日：2009-12-29

申请号：US11824340

申请日：2007-06-28

Applicant: Joram Slager ,  Aron B. Anderson

Inventor： Joram Slager ,  Aron B. Anderson

IPC: G01N33/558

CPC classification number: A61L27/48 ,  A61L27/54 ,  A61L31/129 ,  A61L31/16 ,  A61L2300/252 ,  A61L2300/256 ,  A61L2300/622 ,  C08L71/02 ,  C08L31/04 ,  C08L33/10

Abstract: The present invention is directed to polymeric matrices for the controlled release of a hydrophilic bioactive agent. Generally, the elution control matrix includes a polymeric matrix having a first polymer and a plurality of microparticles that include the hydrophilic bioactive agent. In one embodiment, the matrix includes a polymer comprising hydrophilic and hydrophobic portions. In another embodiment, the microparticles include a crosslinked hydrophilic polymer.

Abstract translation: 本发明涉及用于控制释放亲水生物活性剂的聚合物基质。 通常，洗脱控制基质包括具有第一聚合物和包含亲水生物活性剂的多个微粒的聚合物基质。 在一个实施方案中，基质包括包含亲水和疏水部分的聚合物。 在另一个实施方案中，微粒包括交联的亲水性聚合物。

公开(公告)号：US20090028956A1

公开(公告)日：2009-01-29

申请号：US12215504

申请日：2008-06-27

Applicant: Joram Slager ,  John V. Wall

Inventor： Joram Slager ,  John V. Wall

IPC: A61K9/14 ,  A61K38/02 ,  A61K39/395 ,  A61P43/00

CPC classification number: A61K9/1658 ,  A61K9/5052

Abstract: The invention provides polypeptide microparticles and methods for the preparation thereof using a nucleating agent.

Abstract translation: 本发明提供了多肽微粒及其使用成核剂制备的方法。

公开(公告)号：US08883208B2

公开(公告)日：2014-11-11

申请号：US12756632

申请日：2010-04-08

Applicant: Joseph Schmidt McGonigle ,  Joram Slager

Inventor： Joseph Schmidt McGonigle ,  Joram Slager

IPC: A61L27/48 ,  A61K9/50 ,  A61L17/00 ,  A61L29/12 ,  C12N15/89 ,  A61K9/16 ,  A61K48/00 ,  A61L31/12 ,  A61L17/12 ,  A61L27/54 ,  A61L31/16 ,  A61L29/14 ,  A61K9/00

CPC classification number: A61K9/1641 ,  A61K9/0024 ,  A61K9/1647 ,  A61K9/5084 ,  A61K48/0041 ,  A61L17/005 ,  A61L17/12 ,  A61L27/48 ,  A61L27/54 ,  A61L29/126 ,  A61L29/148 ,  A61L31/129 ,  A61L31/16 ,  A61L2300/258 ,  A61L2300/62 ,  C12N15/89 ,  C08L67/04

Abstract: Embodiments of the invention include devices and methods for the release of nucleic acid complexes. In an embodiment the invention includes a nucleic acid delivery particle. The delivery particle can include a polymeric matrix including a polyethyleneglycol containing copolymer and a nucleic acid complex disposed within the polymeric matrix. The nucleic acid complex can include a nucleic acid and a carrier agent. In an embodiment the invention includes a medical device including a first polymeric matrix comprising a first polymer and a plurality of nucleic acid delivery particles disposed within the first polymeric matrix. The medical device can be configured to release the nucleic acid complex when the medical device is implanted within a subject. Other embodiments are included herein.

Abstract translation: 本发明的实施方案包括用于释放核酸复合物的装置和方法。 在一个实施方案中，本发明包括核酸递送颗粒。 递送颗粒可以包括聚合物基质，其包含含聚乙二醇的共聚物和设置在聚合物基质内的核酸复合物。 核酸复合物可以包括核酸和载体试剂。 在一个实施方案中，本发明包括医疗装置，其包括第一聚合物基质，其包含第一聚合物和设置在第一聚合物基质内的多个核酸递送颗粒。 医疗装置可被配置为当将医疗装置植入受试者内时释放核酸复合物。 本文还包括其它实施例。

公开(公告)号：US08697105B2

公开(公告)日：2014-04-15

申请号：US13074212

申请日：2011-03-29

Applicant: Joram Slager

Inventor： Joram Slager

IPC: A61F13/00 ,  A61K9/00 ,  A61K38/00 ,  A61K31/7088 ,  A61K47/30 ,  A61K47/36 ,  A61P27/06 ,  A61P27/12

CPC classification number: A61K9/0024 ,  A61F9/00 ,  A61K9/0051 ,  A61K9/06 ,  A61K47/36 ,  C08B30/18 ,  C08B31/006 ,  C08J3/075 ,  C08J2305/00

Abstract: The invention provides an injectable formulation that includes an active agent; a biocompatible solvent system, crosslinkable polymers such as polysaccharides; and crosslinking agents; wherein the formulation is substantially free of water. The invention also provides a drug delivery depot formed from the injectable formulation wherein the polymers crosslink in the presence of water in the body of a patient, or in the air, prior to implantation in the patient. Also provided are methods of treatment using such formulations and drug delivery systems.

Abstract translation: 本发明提供了包含活性剂的可注射制剂; 生物相容性溶剂体系，可交联聚合物如多糖; 和交联剂; 其中所述制剂基本上不含水。 本发明还提供由可注射制剂形成的药物递送贮库，其中在植入患者之前，聚合物在患者身体或空气中的水存在下交联。 还提供了使用这种制剂和药物递送系统的治疗方法。

公开(公告)号：US20110229457A1

公开(公告)日：2011-09-22

申请号：US13046547

申请日：2011-03-11

Applicant: Timothy M. Kloke ,  Joram Slager ,  Laxma Gundlapally Reddy ,  David E. Babcock

Inventor： Timothy M. Kloke ,  Joram Slager ,  Laxma Gundlapally Reddy ,  David E. Babcock

IPC: A61K39/395 ,  A61K47/36 ,  A61K38/02 ,  A61K38/43 ,  A61K31/713 ,  A61P25/28 ,  A61P25/16 ,  A61P25/00 ,  A61P27/02 ,  A61P27/06 ,  A61P31/20 ,  A61P31/14 ,  A61P19/02 ,  A61K31/7088 ,  A61K31/7052

CPC classification number: A61K9/0024 ,  A61K9/0051 ,  A61K47/10 ,  A61K47/14 ,  A61K47/36 ,  A61K47/40 ,  C07K16/00 ,  C07K2317/55

Abstract: The invention provides a formulation that includes a biocompatible solvent system, a biodegradable polymer that is substantially soluble in the biocompatible solvent system, and an active pharmaceutical ingredient that is substantially insoluble in the biocompatible solvent system. The formulation can form a drug-eluting implant, when injected into mammalian tissue. The solvent system and the biodegradable polymer can be selected so that the implant provides extended, delayed, controlled and/or modified release of the active pharmaceutical ingredient, for example, over the course of days, weeks or months.

Abstract translation: 本发明提供了一种制剂，其包括生物相容性溶剂体系，基本上可溶于生物相容性溶剂体系的可生物降解聚合物，以及基本上不溶于生物相容性溶剂体系的活性药物成分。 当注射到哺乳动物组织中时，制剂可以形成药物洗脱植入物。 可以选择溶剂体系和可生物降解的聚合物，使得植入物提供活性药物成分的延长，延迟，受控和/或修饰释放，例如在数天，数周或数月的过程中。

公开(公告)号：US20110076337A1

公开(公告)日：2011-03-31

申请号：US12894983

申请日：2010-09-30

Applicant: Joram Slager ,  Aleksey V. Kurdyumov ,  Dale G. Swan

Inventor： Joram Slager ,  Aleksey V. Kurdyumov ,  Dale G. Swan

IPC: A61K9/107 ,  A61K47/36

CPC classification number: A61K9/107 ,  A61K9/0019 ,  A61K9/0024 ,  A61K9/113 ,  A61K9/5036

Abstract: The invention provides emulsion compositions that include a hydrophobic compound and an arylboronic acid. An exemplary emulsion comprises a hydrophobic polymer and a halogenated arylboronic acid. Use of an arylboronic acid provides the emulsion with exceptional stability. The stability provides advantages for the formation of articles formed from the emulsion, including microparticles, as well as other implantable or injectable medical articles having polymeric matrices.

Abstract translation: 本发明提供了包含疏水化合物和芳基硼​​酸的乳液组合物。 示例性的乳液包含疏水性聚合物和卤代芳基硼酸。 使用芳基硼酸提供了非常稳定的乳液。 稳定性为形成由乳液形成的制品提供了优点，包括微粒，以及具有聚合物基质的其它可植入或可注射的医疗制品。

公开(公告)号：US20080020045A1

公开(公告)日：2008-01-24

申请号：US11770316

申请日：2007-06-28

Applicant: Ralph Chappa ,  Robert Hergenrother ,  Paula Bushendorf ,  Joram Slager

Inventor： Ralph Chappa ,  Robert Hergenrother ,  Paula Bushendorf ,  Joram Slager

IPC: A61K47/30 ,  A61K38/02 ,  A61K9/00 ,  A61K39/395

CPC classification number: A61L27/58 ,  A61L27/48 ,  A61L27/54 ,  A61L2300/252 ,  A61L2300/256 ,  A61L2300/604 ,  C08L23/0853 ,  C08L23/0869 ,  C08L33/08 ,  C08L71/02 ,  C08L2201/06 ,  C08L2666/22

Abstract: The present invention relates to relates to combination degradable and non-degradable matrices and related methods. In an embodiment, the invention includes an active agent delivery matrix including a degradable polymer network, a non-degradable polymer network, the non-degradable polymer network interspersed within the degradable polymer network, and an active agent. In an embodiment, the invention includes an active agent elution control matrix including a degradable polymer; and a non-degradable polymer interspersed with the degradable polymer. In an embodiment, the invention includes a method of making an active agent delivery matrix including mixing a degradable polymer with a first solvent to form a degradable polymer solution; mixing a non-degradable polymer with a second solvent to form a non-degradable polymer solution; and simultaneously depositing the degradable polymer solution and the non-degradable polymer solution onto a substrate.

Abstract translation: 本发明涉及可降解和不可降解的基质和相关方法。 在一个实施方案中，本发明包括活性剂递送基质，其包括可降解聚合物网络，不可降解聚合物网络，散布在可降解聚合物网络内的不可降解聚合物网络和活性剂。 在一个实施方案中，本发明包括包含可降解聚合物的活性剂洗脱控制基质; 和散布有可降解聚合物的不可降解聚合物。 在一个实施方案中，本发明包括制备活性剂递送基质的方法，包括将可降解聚合物与第一溶剂混合以形成可降解的聚合物溶液; 将不可降解的聚合物与第二溶剂混合以形成不可降解的聚合物溶液; 同时将可降解聚合物溶液和不可降解聚合物溶液沉积在基材上。

公开(公告)号：US08936811B2

公开(公告)日：2015-01-20

申请号：US12437287

申请日：2009-05-07

Applicant: Joram Slager ,  Joseph Schmidt McGonigle

Inventor： Joram Slager ,  Joseph Schmidt McGonigle

IPC: A61K9/14 ,  A61K31/7052 ,  A61P43/00

CPC classification number: A61K9/1641 ,  A61K9/0024 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1658 ,  A61K47/543 ,  A61K47/58 ,  A61K47/59 ,  A61K47/593 ,  A61K47/60 ,  A61K47/61 ,  A61K47/6921 ,  A61K47/6923 ,  A61K47/6957 ,  A61K48/00 ,  C12N15/87

Abstract: Embodiments of the invention include particles with nucleic acid complexes, medical devices including the same and related methods. In an embodiment, the invention can include a method of making a medical device. The method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, adsorbing the nucleic acid complexes to porous particles to form nucleic acid complex containing particles, mixing the nucleic acid complex containing particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the method can include contacting nucleic acids with cationic carrier agents to form nucleic acid complexes, combining the nucleic acid complexes with a material to form nucleic acid complex containing particles in situ, mixing the nucleic acid complex particles with a polymer solution to form a coating mixture, and applying the coating mixture to a substrate. In an embodiment, the invention can include an implantable medical device including a substrate, an elution control matrix disposed on the substrate; a plurality of particles disposed within the elution control matrix, and a plurality of nucleic acid complexes disposed within the particles, the nucleic acid complexes comprising a nucleic acid and a cationic carrier agent. Other embodiments are included herein.

Abstract translation: 本发明的实施方案包括具有核酸复合物的颗粒，包括相同方法的医疗装置。 在一个实施例中，本发明可以包括制造医疗装置的方法。 该方法可以包括使核酸与阳离子载体接触以形成核酸复合物，将核酸复合物吸附到多孔颗粒上以形成含有核酸复合物的颗粒，将含有核酸复合物的颗粒与聚合物溶液混合以形成涂层混合物， 并将涂覆混合物施加到基底上。 在一个实施方案中，该方法可以包括使核酸与阳离子载体试剂接触以形成核酸复合物，将核酸复合物与材料组合以形成原位含有颗粒的核酸复合物，将核酸复合物颗粒与聚合物溶液混合 形成涂料混合物，并将涂料混合物施加到基材上。 在一个实施例中，本发明可以包括可植入医疗装置，其包括基底，设置在基底上的洗脱控制矩阵; 布置在洗脱控制基质内的多个颗粒，以及设置在颗粒内的多个核酸复合物，所述核酸复合物包含核酸和阳离子载体试剂。 本文还包括其它实施例。